Table 3 Detailed second-line therapy and PFS from first- and second-line therapy in patients who received second-line
From: Systemic treatment in patients with malignant pleural mesothelioma – real life experience
Patient No | PFS from first-line (months) Cisplatin/Pemetrexed | Second-line therapy | PFS from second-line (months) |
|---|---|---|---|
1 | 7.1 | Gemcitabine | 1.2 |
2 | 10.1 | Cisplatin/Pemetrexed | 5.1 |
3 | 10.9 | Cisplatin/Pemetrexed | 2.9 |
4 | 11.1 | Cisplatin/Pemetrexed | 9.8 |
5 | 13 | Vinorelbine | 22.1 |
6 | 16.8 | Cisplatin/Pemetrexed | 11.9 |
7 | 26.3 | Cisplatin/Pemetrexed | 2.1 |
8 | 44 | Cisplatin/Pemetrexed | 39.0 |
9 | 5.3 | Adriamycin/Vincristine/Methotrexate | 2.7 |
10 | 7 | Gemcitabine | 3.5 |
11 | 8.7 | Cisplatin + Pemetrexed | 2.1 |
12 | 8.1 | Vinorelbine | 4 |